As our primary focus was to investigate the impact of HMGB1 knockdown on hyperglycemia and glucose metabolism, we opted to induce only hyperglycemia without introducing obesity and dyslipidemia by only administering low-dose STZ injections over a five-day period. The gene discussed is HMGB1; the disease is obesity disorder.